Precigen(PGEN)
GERMANTOWN, MDBiotechnology
Focus: Precigen is a publicly-traded biotechnology company specializing in cell and gene therapy, with a diversified pipeline spanning oncology, infectious disease, and metabolic disorders. As a mid-cap biotech, the company operates with significant R&D investment and emerging clinical-stage programs.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
11-1 this month
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Should You Work at Precigen?
AI assessmentA high-risk, high-science opportunity best suited for early-career scientists willing to bet on platform validation before financial viability is proven.
Why Work Here
- Recent FDA Platform Technology Designation for AdenoVerse platform signals regulatory momentum and validates core technology approach.
- Diversified pipeline across 8 active programs spanning CAR-T, gene therapy, and immunotherapy modalities offers broad scientific exposure.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$6M
Pipeline & Clinical Trials
INXN-4001
Heart FailureClinical Trials (1)
NCT03409627Novel INXN-4001 Triple Effector Plasmid in Heart Failure
Phase 1Help build intelligence for Precigen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.